Form 4: Edgewise CEO Koch Reports Major Equity Grants

Edgewise Therapeutics CEO Kevin Koch disclosed the vesting of restricted stock units, a tax-related stock sale, and substantial new equity grants including RSUs and stock options.

Summary

• CEO Kevin Koch reported transactions on August 12, 2025, involving Edgewise Therapeutics, Inc. (EWTX) common stock and derivative securities.
• 17,968 shares of common stock were acquired due to the vesting of Restricted Stock Units (RSUs) at a price of $0.00.
• 7,972 shares of common stock were sold at an average price of $13.3924 to cover statutory tax withholding obligations related to RSU vesting; this was not a discretionary sale.
• 53,907 Restricted Stock Units (RSUs) remain directly owned after the reported transactions, with vesting in four equal annual installments beginning August 12, 2025, and an expiration date of August 12, 2034.
• 87,500 new Restricted Stock Units (RSUs) were granted at a price of $0.00, vesting in four equal annual installments beginning August 12, 2026, and expiring on August 12, 2035.
• 525,000 new stock options were granted with an exercise price of $13.39, vesting 1/48th each month beginning September 12, 2025, and expiring on August 12, 2035.
• Direct beneficial ownership of common stock following these transactions is 30,615 shares.
• Indirect beneficial ownership of common stock totals 338,784 shares, held through KTK Family Enterprise, LLC (259,554 shares), Adrienne R. Koch Heritage Trust (26,410 shares), Matthew K. Koch Heritage Trust (26,410 shares), and Nicole M. Soldow Heritage Trust (26,410 shares).
• A previous error of reporting duplicate 26,410 indirectly held shares in prior Form 4 filings was corrected.

Sentiment

Score: 7

Explanation: The filing indicates a strong commitment from the CEO through substantial new equity grants (RSUs and stock options) with long vesting periods, aligning his interests with long-term shareholder value. The stock sale was non-discretionary for tax purposes, not a divestment of confidence.

Positives

• Significant new equity grants, including 87,500 Restricted Stock Units and 525,000 stock options, align the CEO's long-term interests with shareholder value.
• The sale of 7,972 shares was explicitly stated as non-discretionary, solely to cover statutory tax withholding obligations, indicating no intent to reduce personal stake.
• The correction of a previous reporting error regarding duplicate indirect share holdings demonstrates transparency and accuracy in disclosures.

Negatives

• A portion of vested shares (7,972) was sold, which, despite being for tax purposes, reduces the CEO's direct common stock holdings.

Future Outlook

The significant new equity grants to the CEO, with vesting schedules extending to 2035, indicate a long-term commitment to the company's future performance and align executive incentives with shareholder value creation over the coming decade.

Industry Context

This Form 4 filing reflects standard executive compensation practices in the biotechnology or pharmaceutical industry, where equity grants like RSUs and stock options are common tools to incentivize long-term performance and retain key leadership.

Comparison to Industry Standards

• The equity compensation structure, including RSUs and stock options with multi-year vesting schedules, is consistent with typical executive incentive plans observed in comparable biotech companies.
• Similar structures are seen at companies like Sarepta Therapeutics (SRPT) or BioMarin Pharmaceutical (BMRN), where executive compensation often includes a significant equity component tied to long-term performance and retention.

Stakeholder Impact

• Shareholders: The significant equity grants to the CEO align his long-term financial interests with the company's performance, potentially benefiting shareholders through sustained leadership and strategic focus.
• Employees: While not directly impacting general employees, the CEO's continued commitment and long-term incentives may signal stability and confidence in the company's future direction.

Next Steps

• Monthly vesting of 525,000 stock options begins on September 12, 2025.
• Annual vesting of 17,968 RSUs begins on August 12, 2025.
• Annual vesting of 87,500 new RSUs begins on August 12, 2026.

Key Dates

Recommendation

The filing primarily details executive compensation, showing the CEO's continued long-term commitment to Edgewise Therapeutics through significant new equity grants (RSUs and stock options) with multi-year vesting schedules. While there was a sale of shares, it was explicitly stated as non-discretionary for tax withholding, not a signal of reduced confidence. This indicates alignment of management's interests with shareholders over the long term, which is generally positive, but the filing itself does not provide new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Edgewise Therapeutics, EWTX, Kevin Koch, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, CEO, Beneficial Ownership